Biogen (BUE:BIIB) Sale Of Investment : ARS2,369,731 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Sale Of Investment?

Biogen's sale of investment for the three months ended in Mar. 2024 was ARS46,843 Mil. It means Biogen gained ARS46,843 Mil from selling investments. Biogen's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was ARS2,369,731 Mil.

Compared with last quarter (ARS4,837 Mil in Dec. 2023 ), Biogen gained more money from selling investments in Mar. 2024 (ARS46,843 Mil).

Biogen Sale Of Investment Historical Data

The historical data trend for Biogen's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Sale Of Investment Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

387,709.50

600,120.51

353,353.90

615,443.13

2,707,644.40

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sale Of Investment	Get a 7-Day Free Trial															87,020.78	322,776.00	1,995,274.98	4,837.40	46,843.00

Biogen Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS2,369,731 Mil.

Biogen Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Biogen's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.